Center for Paralysis Research, School of Veterinary Medicine, Purdue University, W. Lafayette, IN 47907, USA.
Exp Neurol. 2012 Jan;233(1):126-44. doi: 10.1016/j.expneurol.2011.09.028. Epub 2011 Oct 1.
The hydrophilic polymer PEG and its related derivatives, have served as therapeutic agents to reconstruct the phospholipid bilayers of damaged cell membranes by erasing defects in the plasmalemma. The special attributes of hydrophilic polymers when in contact with cell membranes have been used for several decades since these well-known properties have been exploited in the manufacture of monoclonal antibodies. However, while traditional therapeutic efforts to combat traumatic injuries of the central nervous system (CNS) have not been successful, nanotechnology-based drug delivery has become a new emerging strategy with the additional promise of targeted membrane repair. As such, this potential use of nanotechnology provides new avenues for nanomedicine that uses nanoparticles themselves as the therapeutic agent in addition to their other functionalities. Here we will specifically address new advances in experimental treatment of Spinal Cord and Traumatic Brain injury (SCI and TBI respectively). We focus on the concept of repair of the neurolemma and axolemma in the acute stage of injury, with less emphasis on the worthwhile, and voluminous, issues concerning regenerative medicine/nanomedicine. It is not that the two are mutually exclusive - they are not. However, the survival of the neuron and the tissues of white matter are critical to any further success in what will likely be a multi-component therapy for TBI and SCI. This review includes a brief explanation of the characteristics of traumatic spinal cord injury SCI, the biological basis of the injuries, and the treatment opportunities of current polymer-based therapies. In particular, we update our own progress in such applications for CNS injuries with various suggestions and discussion, primarily nanocarrier-based drug delivery systems. The application of nanoparticles as drug-delivery vehicles to the CNS may likely be advantageous over existing molecular-based therapies. As a "proof-of-concept", we will discuss the recent investigations that have preferentially facilitated repair and functional recovery from breaches in neural membranes via rapid sealing and reassembly of the compromised site with silica or chitosan nanoparticles.
亲水性聚合物聚乙二醇(PEG)及其相关衍生物已被用作治疗剂,通过消除质膜缺陷来重建受损细胞膜的磷脂双层。几十年来,亲水性聚合物与细胞膜接触时的特殊属性一直被用于制造单克隆抗体,因为这些众所周知的特性已被用于制造单克隆抗体。然而,尽管传统的治疗中枢神经系统(CNS)创伤的方法尚未成功,但基于纳米技术的药物输送已成为一种新的新兴策略,其额外的承诺是靶向膜修复。因此,纳米技术的这种潜在用途为纳米医学提供了新的途径,纳米医学除了具有其他功能外,还将纳米颗粒本身用作治疗剂。在这里,我们将特别讨论脊髓和创伤性脑损伤(分别为 SCI 和 TBI)的实验治疗的新进展。我们专注于神经膜和轴突膜在损伤急性期的修复概念,而较少关注再生医学/纳米医学中值得关注的大量问题。并不是说两者相互排斥——它们不是。然而,神经元和白质组织的存活对于 TBI 和 SCI 的多组分治疗可能是至关重要的。本综述简要介绍了创伤性脊髓损伤 SCI 的特征、损伤的生物学基础以及当前基于聚合物的治疗机会。特别是,我们用各种建议和讨论,主要是基于纳米载体的药物输送系统,更新了我们在 CNS 损伤方面的最新进展。纳米颗粒作为药物输送载体应用于 CNS 可能比现有的基于分子的治疗方法更有优势。作为“概念验证”,我们将讨论最近的研究进展,这些研究进展通过使用硅或壳聚糖纳米颗粒快速密封和重新组装受损部位,优先促进了神经膜破裂后的修复和功能恢复。